bluuebunny/crossref_metadata_2025_split huggingface dataset:
Predictive factors of no response during neoadjuvant chemotherapy in breast cancer.
Authors: Jo Jungmin , Yoo Changhoon , Kim Jeong-Eun , Ahn Jin-Hee , Kim Sung-Bae , Kim Hak-Hee , Cha Joo Hee , Shin Hee Jung , Ahn Sei-Hyun , Son Byung Ho , Lee Jong Won , Kim Hee Jeong , Gong Gyungyub , Jung Kyung Hae 
Published: March 2020

e11508 Background: Neoadjuvant chemotherapy (NACT) has been the standard for patients with inflammatory (IBC) and locally advanced breast cancer (LABC) and increases breast conservation rates in patients with operable tumor. Pathologic complete response (pCR) after NACT has been accepted as a marker for improved long-term outcome and predictors of pCR have been reported in many trials. However, predictors of progression or stable disease have been limitedly reported. We aimed to identify predictors of no response during NACT to identify patients who might benefit from an alternative approach. Methods: The medical records of patients with breast cancer who received NACT were reviewed retrospectively at a single center. Between March 2000 and January 2010, 316 patients were enrolled with stage I to III breast cancer. Statistical analyses were performed to compare patients with any response (RG) with patients with progression or stable disease (NRG). Results: Out of 316 patients, 263 patients (83.2%) had some response, 36 (11.4%) had SD, and 17 (5.4%) had PD during NACT. Factors predictive of NRG included nodal (N) status (p=.007) and clinical stage (p=.004), IBC cancer type (p=.02), negative estrogen receptor (ER) status, and negative HER2 status (p=0.04). Pre-NACT N stage, ER status, cancer type, and treatment with trastuzumab were independent predictors of NRG in multivariate analysis. NRG was a negative predictor of disease-free survival (p=.002) and overall survival (p=.026) in multivariate analysis. Conclusions: Factors predicting NRG include advanced nodal stage, ER negativity, IBC and NACT without trastuzumab in HER2-positve tumors. Because these variables are associated with poor prognosis, novel targeted therapies and molecular predictors are needed to improve outcome
Mixed metabolic response on PET/CT in patients with metastatic breast cancer as an early predictor of disease progression.
Authors: Sen Urmi , Ling Huichung Tina , Chhabra Akansha , Friedman Kent P , Tiersten Amy 
Published: March 2020

e11522 Background: It has been observed that patients undergoing systemic therapy for metastatic breast cancer (MBC) may demonstrate a mixed metabolic treatment response on FDG PET (MMTR) while maintaining stable disease on CT (SDCT). The purpose of this study is to determine (1) the clinical outcome of MBC patients demonstrating MMTR+SDCT who were maintained on the same treatment regimen and (2) the behavior of oncologists when faced with a report of MMTR+SDCT. Methods: All FDG PET/CT scan reports performed at one institution between 2006-2011 were searched and studies describing a MMTR also containing the term “breast cancer” were identified. MBC patients without other active malignancies were extracted from the search and scans were re-analyzed. MMTR was defined as a PET/CT scan demonstrating a minimum of 2 lesions with a SUVmax change of +25% or more combined with at least 2 lesions demonstrating a SUVmax change of -25% or more. The subset of patients with MMTR+SDCT (by anatomical RECIST criteria) who were maintained on their current treatment regimen was further examined to identify time to progression (TTP). Results: Thirty-two cases were identified that demonstrated MMTR+SDCT in metastatic breast cancer patients. No change in therapy occurred within 3 months of the scan in 9/32 patients. Of the 9 patients who were maintained on their current treatment regimen, 5 patients demonstrated subsequent disease progression at 3 (n=2), 5 (n=2), and 11 (n=1) months (mean TTP = 5.4 months, range 3-11 months). One patient remains stable at 16 months and 3 patients have insufficient follow-up. Therapy was changed immediately after the scan in the remaining 22 patients for various reasons including preference of the treating oncologists, treatment toxicities, increase in tumor markers, or clinical progression. Conclusions: MMTR+SDCT in patients with MBC predicted subsequent disease progression within 6 months in the majority of individuals. Oncologists commonly alter treatment regimen when faced with a report of MMTR+SDCT. Based on the observation of outcomes in patients who did not change therapy, this practice seems justified.
Gemcitabine (G) and cisplatin (C) as first-line treatment of metastatic breast cancer (MBC): Results of phase II trial.
Authors: Karthaus Meinolf , Poddubnaya Irina , Churilova L. , Khazanov R. , Veremeychuk T. , Rumyantzeva E , Garin M. , Brichkova O. , Heinrich Bernhard , Heinemann Volker 
Published: March 2020

e11528 Background: G has been studied in combination with a variety of agents known to be active in cancer. G has a mild toxicity profile. GC is active in various advanced tumors. Splitting of C dose (d1 + d8) is better tolerated and can be a good alternative to once a cycle in pts with advanced breast cancer. This phase II trial evaluates G (1000 mg/m2) C (35 mg/ m2) d1+d8 repeated every 21 d in the 1st-line treatment of metastatic breast cancer (MBC). The primary objective of the study was to determine the objective tumor response rate (ORR) of 1st-line GC in patients with metastatic breast cancer. The one-stage design tested the null hypothesis that the true response rate for this population should be equal to 50% for efficacy. Overall survival (OS), time to progression (TTP) and toxicity were evaluated. Methods: 70 female MBC pts with the median age of 49.8 yrs (range 29.6-80.0) were enrolled. Tumor assessment was performed every other cycle by standard criteria including CT or MRI. 67 pts received a total of 310 cycles GC, out of these 54 pts were evaluable for efficacy. Results: Complete and partial responses were observed in 7/54 (13.0%) and 19/54 (35.2%) evaluable pts, respectively with an overall response of 48.1%. Disease stabilization was noticed in 19/54 (35.2%) pts. Progression was observed in 5/54 (9.3%) pts. Median TTP was 33.9 weeks (95% CI, 23.9-48.0). Median OS was 84.0 weeks (95% CI, 58.6-119.3). 1-year overall survival rate was 68.4% (95% CI, 53.6-79.3%). Hematological toxicity G4 was neutropenia in 14.9% (10/67), and no G4 thrombocytopenia. Hypotension G4 (1.5%) was the only severe non-hematological toxicity. Conclusions: GC in the first-line treatment of MBC demonstrated a substantial overall response rate and had a good toxicity profile. GC is a suitable option for first-line MBC in selected pts.
Factors affecting survival in upfront metastatic breast carcinoma patients.
Authors: Uyeturk Ummugul , Budakoglu Burcin , Turker Ibrahim , Helvaci Kaan , Uysal Sonmez Ozlem , Yalçintas Arslan Ülkü , Oksuzoglu Omur Berna 
Published: March 2020

e11540 Background: Metastatic breast cancer is a heterogenous disease. There are several subgroups according to pathological, biological and molecular behaviours of the tumor. Recurrent metastatic breast carcinoma (RMBC) and upfront metastatic breast carcinoma (UMBC) may differ according to clinical and prognostic characteristics. Intrinsic genetic heterogeneity may be responsible for these differences. To date, little is known about the clinical features and outcome of patients with UMBC. Methods: Patients were considered to have UMBC if patients were admitted to the clinics with stage IV disease. Patients were considered to have RMBC if metastases had developed during followup for localized breast carcinoma. Between September 2007 and May 2011, 102 of 2478 (4.1%) UMBC patients who was admitted to Department of Medical Oncology Clinic, was included in this retrospective trial. Patients’ characteristics, treatment schedules and survival data were evaluated. Results: All patients were female. Median age was 50.0 (range: 26-90). More than half of patients (58.8%) were postmenopausal. Frequent histological type was invasive ductal carcinoma (89.2%). Most of the patients had grade 3 (57.8%) tumor. Hormone receptor (HR) and HER2 positivity were76.5% and 42.2%, respectively. Metastatic sites were visceral, isolated bone-soft tissue and combination in 20%, 42% and 37%, respectively. Most of visceral metastatic patients were HR negative and HER2 positive. Median PFS and OS were 30 and 66 months, respectively. Both PFS and OS were affected from HR status, HER2 status, sites of metastatic disease and chemotherapy (log-rank p=0.006, 0.04, 0.02, 0.004, 0.03 and log-rank p= 0.04, 0.04, 0.01, 0.03, 0.01 respectively). Both PFS and OS were not affected by age, menopausal status, performance status, histology and grade of the tumor. OS were longest in patients group who received chemotherapy (76 months) and shortest in patients group who received chemotherapy and targeted therapy combinations (23 months). Conclusions: Factors affecting survival were comparable to previous studies in UMBC patient population similiar to results RMBC studies. This finding should be confirmed with prospective trials in larger study populations.
Safety and activity of nonpegylated liposomal doxorubicin (nPLD) combined with oral metronomic cyclophosphamide (mC) as preoperative treatment for locally advanced breast cancer (BC) patients (pts).
Authors: Andreis Daniele , Generali Daniele Giulio , Foroni Chiara , Bazzola Letizia , Cappelletti Mariarosa , Zanoni Vanessa , Milani Manuela , Strina Carla , Allevi Giovanni , Aguggini Sergio , Boni Ermenegilda , Giardini Roberto , Bertoni Ramona , Bottini Alberto 
Published: March 2020

e11546 Background: nPLD has the same clinical benefits but less toxicity than the traditional doxorubicin. It’s well reported mC produces anti-proliferative and anti-angiogenic effect in tumours. We conducted a retrospective study to evaluate the safety and activity of the association of nPLD and mC in pts with locally advanced BC. Methods: A total of 41 female pts with HER2-negative locally advanced BC unfit for standard chemotherapy received nPLD 25 mg/mq biweekly for eight courses along with mC 50 mg daily as primary systemic treatment. Toxicity and clinical-radiological response with Ki67 and CD31 expression were evaluated in tumour specimens obtained before and after treatment. Results: Pts characteristics included: median age 47.5 years; 31.7% Luminal A (LA), 56.1% Luminal B (LB), and 12.2% Triple Negative BC subtype classified by immunohistochemistry. The rate of breast-conserving surgery was 59.5%. All pts were evaluable for response. Objective response rate (ORR) was 58.5% (95% confidence interval, 42.1% to 73.7%), with 4 (9.7%) clinical complete responses (CR) and 20 (48.8%) partial responses. Sixteen pts (39.0%) achieved a stable disease and 1 pt progressed. One pt experienced a pathological CR. LA subtype was significantly associated with better ORR than others subtypes (p=0.049) and especially than LB (p=0.040). There was a borderline significant reduction of Ki67 expression after treatment (median, 15.5% to 9%; p=0.056), but no significant variation in CD31 expression (p=0.865). The majority of adverse events (AEs) were mild or moderate. Grade ≥3 AEs included neutropenia (12.2%), vomiting (4.9%) and hyperglycemia (2.44%). Temporary treatment suspension due to toxicity occurred in 8 (19.5%) pts; discontinuation was necessary in 1 pt. No symptoms were related to impairment of cardiac function. Mean left ventricular ejection fraction levels did not change substantially before and after treatment: 58.7% and 57.1%, respectively. Conclusions: The combination of nPLD and mC is well tolerated, with a promising activity as preoperative therapy in unfit pts with locally advanced BC.
Neoadjuvant capecitabine chemotherapy in women with newly diagnosed locally advanced breast cancer in a resource-poor setting (Nigeria): Efficacy and safety in a phase II feasibility study.
Authors: Arowolo Olukayode Adeolu , Njiaju Uchenna O , Ogundiran Temidayo O , Lawal Olukayode O , Obajimi Millicent , Adetiloye Adebayo , Im Hae Kyung , Akinkuolie Akinbolaju Andrew , Oluwasola Abideen Olayiwola , Adelusola Kayode , Adesunkanmi Abdulrusheed Kayode , Agbakwuru Augustine , Falusi Adeyinka , Durosinmin Muheez , Olopade Olusola C , Olopade Olufunmilayo I 
Published: March 2020

e11554 Background: The majority of clinical trials of neoadjuvant therapy for breast cancer have been conducted in resource-rich countries. We chose Nigeria, a resource-poor country, as the major site for a phase II feasibility open label multicenter clinical trial designed to evaluate the efficacy, safety and tolerability of neoadjuvant capecitabine in locally advanced breast cancer. Methods: Planned treatment consisted of 24 weeks of capecitabine at a dose of 1000mg/m2 twice daily (2000mg/m2 total per day). Each cycle consisted of a 14-day period of therapy followed by a 7-day pause, and patients were evaluated after 3 cycles and taken off study if no response was documented. Responding patients were treated for no more than 8 cycles. The primary endpoints were partial, complete clinical response and pathologic complete response. Results: A total of 16 patients were recruited from August 2007 to April 2010. The study was terminated early as a result of slow accrual. After the first 3 cycles of therapy, partial clinical responses were seen in 5 of 16 patients (31%; 95% CI 11% - 59%). Of the remaining 11 patients, 8 had no response or stable disease, and 3 had progressive disease. Seven pateints proceeded with further therapy, two of them with stable disease but exactly in the border line of 25% increase. By physical examination, only 2 of the 6 patients had a documented complete clinical response, while by ultrasonomammography, partial responses were observed in 5 patients. Thus, overall response rate at the end of 8 cycles were 31.1% both by clinical examination and by ultrasonomammography. Clinical response by physical examination and radiologic response by ultrasonomammography were highly concordant (the spearman correlation between the two ratios was 0.70). The most common adverse effect was Grade 1 Hand and Foot Syndrome in 75% of patients. Conclusions: Despite several limitations, we successfully carried out this phase II feasibility study of neoadjuvant capecitabine for locally advanced breast cancer in Nigeria. Capecitabine monotherapy showed good overall response rates with minimal toxicity and further studies are warranted.
Effect of goshajinkigan on peripheral neuropathy in breast cancer patients treated with docetaxel.
Authors: Abe Hajime , Mori Tsuyoshi , Kawai Yuki , Cho Hirotomi , Kubota Yoshihiro , Umeda Tomoko , Mekata Eiji , Tani Tohru 
Published: March 2020

e11564 Background: Although taxanes have become a key chemotherapeutic drug in breast cancer treatment, one of the side effects is peripheral neuropathy. Goshajinkigan (GJG) is a traditional Japanese medicine that is used for the treatment of several neurological symptoms including pain and numbness. Recently, GJG has been reported to prevent anticancer drug-induced peripheral neuropathy in colorectal cancer in the gynecology field. We investigated the efficacy of GJG and mecobalamin (B12) on peripheral neurotoxicity associated with docetaxel (DOC) in breast cancer patients. Methods: Between 2007 and 2011, 60 breast cancer patients were treated with DOC. Thirty-three patients (GJG group) received oral administration of 7.5 g/day GJG every day during DOC therapy and 27 patients (B12 group) received oral administration of 1500 μg/day B12. Peripheral neuropathy was evaluated during every course according to DEB-NTC (Neurotoxicity Criteria of Debiopharm), Common Terminology Criteria for Adverse Events (CTCAE) ver. 3.0, and a visual analogue scale (VAS). Results: The median age of the GJG group was 58 years old (35 to 70 years old), the B12 group was 55 years old (33 to 69 years old), and they were all females. For the regimens, in the GJG group, TC (DOC and cyclophosphamide), DOC only, and XT (capecitabine and DOC) were administered in 19 cases, 13 cases and 1 case, respectively. In the B12 group, they were 15 cases, 11 cases and 12 cases, respectively. The cumulative dose of DOC was 338.5 mg/m2 in the GJG group, and 340 mg/m2 in the B12 group. The completion rate was 100% in both groups. The incidence of peripheral neuropathy was 39.3% in the GJG group, and 88.9% in the B12 group (p < 0.01). In the GJG group, grade 1 DEB-NTC was observed in 2 cases, grade 2 in 5 cases and grade 3 in 5 cases. Grade 1 CTCAE was observed in 7 cases, grade 2 in 6 cases, and VAS was 2.7 ± 2.2. In the B12 group, grades 1, 2 and 3 DEB-NTC were observed in one case, 12 cases and 12 cases, respectively; and grades 1 and 2 CTCAE were observed in 12 cases each, and VAS was 4.9 ± 2.4. Peripheral neuropathy was significantly controlled in the GJG group. Conclusions: Concomitant administration of GJG is useful in preventing peripheral neuropathy in breast cancer patients treated with DOC regimen.
Resection of breast cancer brain metastases: A single institution experience.
Authors: Brady Claire , Bambury Richard Martin , Battley Jodie E , Murray Susan , O'Reilly Seamus , Power Derek G , Moylan Eugene J. , Bermingham Niamh , Keohane Catherine , Karr George , Marks Charles , O' Sullivan Michael GJ 
Published: March 2020

e11569 Background: Resection of a single brain metastasis (SBM) in metastatic cancer has been shown to improve overall survival (OS). A previously reported series from MD Anderson of breast cancer patients undergoing SBM resection reported a median overall survival of 19 months. We report our experience of SBM resection for breast cancer. Methods: Retrospective observational study of patients who underwent resection of SBM from breast cancer brain in a tertiary referral centre from 2000-2011. Results: 20 patients underwent SBM resection from 2000-2011. All patients received WBRT after surgery. 2 patients had progressive metastatic disease presenting as brain metastases. Median time from original breast cancer diagnosis to development of SBM was 53 months (range:1-286months). 9 patients had solitary brain metastases (no metastases elsewhere) and 11 patients had synchronous metastases elsewhere. Regarding the primary breast tumour: 41% of patients were ER+, 57% were HER2+ and 25% were triple negative. 1 patient had discordance of ER status between the primary tumour and brain metastasis (changed from ER- to ER+). Median overall survival was 9 months (95% CI: 5-18 months) with 1 year OS of 50%, 2 year OS of 15% and 3 year OS of 5%. Patients treated between 2006-2011 had better median OS than those treated 2000-2005(18 months vs 6 months – p-value not significant). Patients with a solitary brain metastasis had better median OS than those with synchronous extracranial disease (13 months vs 6 months – p-value not significant). An additional 2 patients underwent craniotomy for presumed breast cancer metastasis but histology revealed glioblastoma multiforme. Conclusions: We report on a cohort of patients undergoing metastatectomy for single brain metastasis from breast cancer. Median OS was 9 months but there was a trend towards better survival in patients treated in recent years when compared with those treated from 2000-2005. Improved systemic therapies may account for this difference. Also of note 2 patients undergoing resection for presumed brain metastases were found to have GBM, highlighting the role of tissue diagnosis in patients presenting with a solitary brain lesion.
Oral health-related quality of life among children undergoing cancer therapy.
Authors: Wong Hai Ming , Chu Chun Hung , Chan Godfrey Chi Fung 
Published: March 2020

e12006 Background: Despite much interest in oral complications in cancer patients and studies reporting their prevalence, aetiology and management, there has been little understanding of how they affect the patients and the family. The aim of this study was, therefore, to assess the impact of oral complications on life quality for children undergoing cancer therapy. Methods: Seventy 6 - 14 years old paediatric patients undergoing cancer therapy in the Department of Paediatrics and Adolescent Medicine, Queen Mary Hospital, Hong Kong participated in this study. A clinical examination of the dentition and oral soft tissues was performed using criteria suggested by the World Health Organization. Clinical examination evaluated the status of: i) dental caries (DMFT/dmft Index), ii) periodontal health (CPI Index), iii) infection, such as herpes and candidiasis, iv) thrombocytopathy in the form of oral petechiae and spontaneous gingival bleeding, v) xerostomia, and vi) mucositis (WHO Mucositis Scale). Two questionnaires were filled by the children and their parents: i) the Child Perceptions Questionnaire (CPQ), and ii) a questionnaire contained simple closed questions to collect the information of oral health habits of children and demographic data from the parents. Results: Higher CPQ scores were found in children with mucositis (p < 0.001), dental caries (p < 0.001), children who were born in mainland China (p < 0.05), or parents of lower education or income level (p < 0.05). In multiple regression analyses, mucositis and dental caries were the significant predictors (p < 0.001) of the higher CPQ scores among the various parents and children characteristics collected in this survey. Conclusions: The findings of this study showed that paediatric cancer patients with mucositis and dental caries had poorer oral health-related quality of life.
Five vitamin D receptor polymorphisms (FokI, BsmI, Apa1, Taq1, and Cdx2) and lung cancer risk.
Authors: Li Rong , Tian Ming , Ma Meili , Pei Jun , Song Yiyi , Han Baohui 
Published: March 2020

e12013 Background: Vitamin D and its receptor (VDR) have been implicated in lung cancer incidence and mortality. Here we assess the relationships between VDR single nucleotide polymorphisms (SNPs) (FokI, BsmI, ApaI, Taq, Cdx2) and lung cancer incidence in Chinese patients. Methods: Genomic DNA was extracted from peripheral blood samples. Five VDR SNPs (FokI, BsmI, ApaI, Taq, Cdx2) were detected by polymerase chain reaction. Genotype analysis was conducted using mass spectrograph. Results: A total of 67 lung cancer patients and 72 healthy controls participated in the study. There were more males and current smokers among the lung cancer patients than among healthy controls. Lung cancer patients were much older than controls. Age and smoking status were included in the equation for predicting disease status. The CC-AA (Apa1-Cdx2) and the CC-AA-CC (ApaI-Cdx2- FokI) haplotypes were associated with higher lung cancer incidence. The rs1544410 (BsmI) and rs731236 (TaqI) were not associated with higher lung cancer incidence, but they were associated with rs797523 (ApaI). Conclusions: There is a significant correlation between certain VDR SNPs (FokI, ApaI, Cdx2) and lung cancer incidence in Chinese people.